Pulmonary arterial hypertension (PAH) has been classically described as a disease in young adults, predominantly females with no comorbidities. However, in recent registries, the epidemiology has changed to older patients with comorbidities such as obesity, diabetes, systemic hypertension, and coronary heart disease. Nevertheless, there is not enough inclusion of these patients in clinical trials. In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present a different phenotype or if we are lagging behind developed countries and whether we will experience a change in epidemiology in the next couple of years. We analyzed these trends in this review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891735 | PMC |
| http://dx.doi.org/10.1016/j.ijcchd.2025.100573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy and pulmonary artery hypertension: Management challenges.
Int J Cardiol Congenit Heart Dis
March 2025
Department of Obstetrics, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Pulmonary hypertension (PH) is a term used to describe a complex heterogenous group of conditions defined by a mean pulmonary arterial pressure of more than 20 mmHg at rest on right-heart catheterization. PH in pregnancy is associated with high rates of maternal morbidity and mortality and poor fetal outcomes. Currently, pregnancy in these women is classified as modified WHO class IV (pregnancy contraindicated).
View Article and Find Full Text PDFPhysical exercise for pulmonary arterial hypertension diagnosis and therapy.
Int J Cardiol Congenit Heart Dis
March 2025
Royal Brompton Hospital, Part of GSTT Foundation Trust, UK.
Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.
Int J Cardiol Congenit Heart Dis
March 2025
From the Cardiopulmonary Department, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.
Pulmonary arterial hypertension (PAH) has been classically described as a disease in young adults, predominantly females with no comorbidities. However, in recent registries, the epidemiology has changed to older patients with comorbidities such as obesity, diabetes, systemic hypertension, and coronary heart disease. Nevertheless, there is not enough inclusion of these patients in clinical trials.
View Article and Find Full Text PDFPulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study) - Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial.
Circ Rep
March 2025
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking.
View Article and Find Full Text PDFA Novel Missense Variant of in Pulmonary Arterial Hypertension.
Circ Rep
March 2025
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute Osaka Japan.
Background: Because Regnase-1, encoded by , suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify variants in patients with PAH.
Methods And Results: We analyzed whole-genome sequence data of patients with PAH to search for disease-associated variants. The Regnase-1 p.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!